The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $2.56 in the prior trading day, Health Catalyst Inc (NASDAQ: HCAT) closed at $2.46, down -3.91%. In other words, the price has decreased by -$3.91 from its previous closing price. On the day, 0.62 million shares were traded. HCAT stock price reached its highest trading level at $2.62 during the session, while it also had its lowest trading level at $2.44.
Ratios:
Our goal is to gain a better understanding of HCAT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.86 and its Current Ratio is at 1.86. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.50.
Cantor Fitzgerald Downgraded its Overweight to Neutral on August 08, 2025, while the target price for the stock was maintained at $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 05 ’25 when Landry Benjamin sold 27,425 shares for $2.64 per share. The transaction valued at 72,328 led to the insider holds 100,000 shares of the business.
Larson-Green Julie sold 47,997 shares of HCAT for $128,349 on Dec 04 ’25. The Director now owns 73,573 shares after completing the transaction at $2.67 per share. On Dec 05 ’25, another insider, BENJAMIN LANDRY, who serves as the Officer of the company, bought 27,425 shares for $2.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 173997968 and an Enterprise Value of 254576976. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.36. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.55 while its Price-to-Book (P/B) ratio in mrq is 0.52. Its current Enterprise Value per Revenue stands at 0.805 whereas that against EBITDA is -15.111.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.68, which has changed by -0.67388535 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $8.50, while it has fallen to a 52-week low of $2.02. The 50-Day Moving Average of the stock is -12.53%, while the 200-Day Moving Average is calculated to be -30.35%.
Shares Statistics:
The stock has traded on average 641.13K shares per day over the past 3-months and 691990 shares per day over the last 10 days, according to various share statistics. A total of 70.62M shares are outstanding, with a floating share count of 66.16M. Insiders hold about 6.60% of the company’s shares, while institutions hold 78.14% stake in the company. Shares short for HCAT as of 1764288000 were 6028208 with a Short Ratio of 9.40, compared to 1761868800 on 6203840. Therefore, it implies a Short% of Shares Outstanding of 6028208 and a Short% of Float of 9.71.
Earnings Estimates
As of right now, 8.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.08, with high estimates of $0.15 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.25 and $0.18 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.35, with 10.0 analysts recommending between $0.62 and $0.21.
Revenue Estimates
11 analysts predict $73.94M in revenue for. The current quarter. It ranges from a high estimate of $75.04M to a low estimate of $73.5M. As of. The current estimate, Health Catalyst Inc’s year-ago sales were $79.61MFor the next quarter, 11 analysts are estimating revenue of $74.21M. There is a high estimate of $76.4M for the next quarter, whereas the lowest estimate is $71.96M.
A total of 12 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $311.49M, while the lowest revenue estimate was $309.9M, resulting in an average revenue estimate of $310.26M. In the same quarter a year ago, actual revenue was $306.58MBased on 12 analysts’ estimates, the company’s revenue will be $302.08M in the next fiscal year. The high estimate is $307.5M and the low estimate is $298.1M.
